On July 17, 2025, the Company received the final grant of NIS 816 (approximately $243) from the IIA in connection with a program approved in August 2021 to support upgrading the Company’s

manufacturing capabilities.

On July 17, 2025, 223 Redeemable Convertible Preferred Shares were converted into 22,300 shares of Common Stock.

In July 2025, BiomX Israel notified the lessor of its intention not to exercise the option to extend the lease agreement for an additional five-year period beginning on December 1, 2025, related to its office space in Ness Ziona, Israel. In accordance with the lease terms, BiomX Israel may be required to repay the lessor the remaining balance of previously reimbursed leasehold improvements costs, amounting to approximately $500. At this stage, BiomX Israel is in preliminary negotiations regarding a modification to the existing lease agreement and is also evaluating potential alternatives.